[HTML][HTML] Trends in prescribing and outcomes in obese versus non-obese patients receiving rivaroxaban therapy: an observational study using real-world data
… The number of patients initiated on rivaroxaban therapy significantly increased from 152 (3.3…
overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban …
overweight patients, while from 2018 to 2020, there was a decreasing trend in rivaroxaban …
Apixaban and rivaroxaban in obese patients treated for venous thromboembolism: drug levels and clinical outcomes
A Ballerie, RN Van, K Lacut, H Galinat, C Rousseau… - Thrombosis research, 2021 - Elsevier
… Concentrations were compared to published reference values for non-obese patients.
Demographic, clinical, biological and therapeutic data were collected. Univariate and multivariate …
Demographic, clinical, biological and therapeutic data were collected. Univariate and multivariate …
[PDF][PDF] Comparative efficacy and safety associated with apixaban and rivaroxaban treatment in morbidly obese versus non-obese patients
MF Duperreault, G Stern, J Rimsans… - Ann Cardiol Vasc …, 2020 - mail.meddocsonline.org
… patients, apixaban and rivaroxaban were not associated with an increased incidence of
treatment failure or major bleeding in MO patients… , apixaban and rivaroxaban may be safe to use …
treatment failure or major bleeding in MO patients… , apixaban and rivaroxaban may be safe to use …
Apixaban and rivaroxaban use for atrial fibrillation in patients with obesity and BMI ≥50 kg/m2
CP O'Kane, JCO Avalon, JL Lacoste… - … and Drug Therapy, 2022 - Wiley Online Library
… Rather than comparing DOACs to warfarin for NVAF in obesity, we compared non-obese
and obese patient groups. This strategy directly compares effectiveness and safety differences …
and obese patient groups. This strategy directly compares effectiveness and safety differences …
Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population
JS Berger, F Laliberté, A Kharat, D Lejeune… - Current Medical …, 2021 - Taylor & Francis
… of treatment assignment. Patients’ weight in each cohort was equal to the inverse of their
probability of receiving treatment with rivaroxaban (ie 1/PS for the rivaroxaban cohort and 1/[1-…
probability of receiving treatment with rivaroxaban (ie 1/PS for the rivaroxaban cohort and 1/[1-…
[HTML][HTML] Real life behaviour of direct oral anticoagulants in patients with nonvalvular atrial fibrillation and morbid obesity
B Navarro-Almenzar, JJ Cerezo-Manchado… - IJC Heart & …, 2021 - Elsevier
… the rivaroxaban group [29], [30]. This increase in major bleeding was seen in both the obese
… non-obese populations and it may be explained by the worse clinical profile of our patients …
… non-obese populations and it may be explained by the worse clinical profile of our patients …
Pharmacokinetics of single‐dose rivaroxaban under fed state in obese vs. non‐obese subjects: An open‐label controlled clinical trial (RIVOBESE‐PK)
M Alalawneh, A Awaisu, I Abdallah… - Clinical and …, 2024 - Wiley Online Library
… The evidence of rivaroxaban's pharmacokinetics in obese compared with non-obese …
We aimed to compare the pharmacokinetic profile of rivaroxaban between obese and non-obese …
We aimed to compare the pharmacokinetic profile of rivaroxaban between obese and non-obese …
Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data
OS Costa, J Beyer-Westendorf, V Ashton… - Current Medical …, 2020 - Taylor & Francis
… 2 1/2 years of patient follow-up, we found prescription of rivaroxaban to be associated with a
… reduction in major bleeding compared to warfarin in NVAF patients with a BMI ≥ 30 kg/m 2 . …
… reduction in major bleeding compared to warfarin in NVAF patients with a BMI ≥ 30 kg/m 2 . …
A Real-World Comparison of Apixaban and Rivaroxaban in Obese and Morbidly Obese Patients With Nonvalvular Atrial Fibrillation
KT Burnham, T Yang, J Wooster - Journal of Pharmacy …, 2024 - journals.sagepub.com
… rivaroxaban for obese patients with NVAF. Real-world observational data for inter-class
comparisons of DOACs for NVAF have been published in recent years, which include non-obese …
comparisons of DOACs for NVAF have been published in recent years, which include non-obese …
[HTML][HTML] Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation
ED Peterson, V Ashton, YW Chen, B Wu… - American heart …, 2019 - Elsevier
… claims databases, we identified patients initiating rivaroxaban or warfarin who had ≥1 … 12
months before and 3 months after treatment initiation. Patients were excluded if they had mitral …
months before and 3 months after treatment initiation. Patients were excluded if they had mitral …
相关搜索
- prescribing and outcomes non-obese patients
- rivaroxaban treatment non-valvular atrial fibrillation
- morbidly obese patients
- direct oral anticoagulants obese patients
- dresden noac registry obese patients
- warfarin in obese patients
- clinical outcomes obese patients
- apixaban and rivaroxaban obese patients
- venous thromboembolism obese patients
- real world data non-obese patients
- observational study non-obese patients
- safety of edoxaban obese patients
- effectiveness and safety obese patients
- comparative effectiveness obese patients
- drug levels rivaroxaban in obese patients
- rivaroxaban treatment japanese patients